Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis

This research evaluated Natalizumab, a monoclonal antibody therapy for relapsing multiple sclerosis. The study examined how this drug reduces disease progression through immune modulation. Using appropriate research methodology, the team measured key disease outcomes and markers. Results advanced understanding of MS pathophysiology and treatment efficacy. The results support Natalizumab as effective therapy while highlighting PML risk assessment.